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Human DNA
Polymerase ι :
Wrong for the
Right Reasons
In a recent collaborative study, Thomas A.
Kunkel, director of the NIEHS Environ-
mental Biology Program, NIEHS deputy
director Samuel H. Wilson, and Roger
Woodgate, an investigator at the National
Institute of Child Health and Human
Development, report novel findings about
DNA repair and genome stability in
humans. Woodgate’s laboratory recently
discovered and purified polymerase iota (pol
ι ), one of a superfamily of DNA polymerases
that synthesize short stretches of DNA and
are relatively inaccurate—that is, they may
allow the A, C, G, or T base moieties to be
matched to an incorrect mate (for instance,
matching G with T or A, rather than with
its proper mate, C). The scientists speculate
that these enzymes’ importance therefore
lies in DNA repair and damage-induced
mutagenesis, not in DNA replication. 
The highly accurate DNA polymerases
that carry out DNA replication are blocked
by DNA damage. In contrast, some of the
less accurate polymerases, also called
translesion synthesis (TLS) polymerases,
bypass damage in the DNA, fall off after
inserting a few nucleotides, and then allow
an accurate replicative polymerase to con-
tinue. Thus, TLS polymerases may allow
damaged cells to survive at the cost of a
slightly higher mutation rate in regions of
DNA damage. 
The results of the collaboration
between the Kunkel, Wilson, and
Woodgate laboratories, published in the
16 March 2001 issue of Science, indicate
that pol ι has a novel enzymatic activity
called 5′ -dRPase, which removes damage
from the 5′ end of a broken DNA strand.
This activity was previously demonstrated
in polymerase beta, which is active in a
repair pathway called base excision repair
(BER). dRPase activity is required during
many BER reactions, suggesting that pol ι
could participate in BER. 
In addition, Kunkel and colleagues
show that the sequence of DNA in question
greatly influences whether pol ι forms a cor-
rect base pair (namely AT, TA, GC, or CG)
or an incorrect base pair (for example, GT).
Pol ι forms an AT base pair inserting T
opposite A 40- to 100-fold more efficiently
than it forms the other correct base pairs, a
property that had not been reported previ-
ously. However, says Kunkel, “The most
unusual thing about pol ι is its preference
to insert G opposite T rather than A oppo-
site T.” The rate at which pol ι makes this
error during DNA synthesis is higher than
observed for any base pair. Based on their
results, Kunkel and colleagues suggest two
novel roles for pol ι in BER. 
In the first possible role, pol ι may play
a role repairing uracil (U) in DNA. U is a
normal, correct base in RNA that is not
found in normal undamaged DNA. It
forms in DNA spontaneously and enzymat-
ically when a C base undergoes a normal
damage process known as deamination. It
can also be misinserted during normal
DNA replication. In this role, U is
removed enzymatically from an incorrect
AU base pair, and then pol ι replaces it
with T, a reaction that calls on the dRPase
activity of pol ι and that is highly accurate. 
In the second role, pol ι could also pre-
vent misrepair of GT mismatches. In this
scenario, a GT base pair forms sponta-
neously when C undergoes deamination.
When this occurs, G is the correct base
and T is the incorrect base in the mispair.
The incorrect T base should be removed
and replaced with a C base, but if the cor-
rect G is removed instead, a mutation
could result. In this case, Kunkel and col-
leagues suggest that pol ι might reinsert G
opposite T as a “correct” insertion event
that stabilizes the genome, allowing the
normal sequence to be restored. 
This is a surprising suggestion, because
it is thought that TLS polymerases are
inaccurate and that they form mispairs that
increase the mutation rate. Kunkel’s idea is
that pol ι forms a mispair in a specific con-
text where it actually decreases the muta-
tion rate. Errol Friedberg, a professor of
pathology at the University of Texas
Southwestern Medical Center at Dallas,
finds this “a very interesting idea” that sug-
gests that these polymerases “may have
very specialized functions that allow them
to be error-free.” 
Friedberg points out that “the bio-
chemical evidence needs to be backed up
by genetic evidence” in order to establish
the full extent of the role or roles of pol ι
in vivo. It is clear that pol ι creates errors
with high frequency in certain sequence
contexts; thus, this enzyme, like other
TLS polymerases, must be tightly regulat-
ed in vivo. More research is needed to
clarify the biologic roles and the regula-
tion of pol ι and other TLS polymerases.
–Miriam Sander
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Group to Target
Autoimmune
Disorders 
A recently formed clinical research group
will soon begin studying how the complex
interplay between genetics and the envi-
ronment may influence the
development of autoimmune dis-
orders. Working out of the
NIH’s Warren Grant Magnuson
Clinical Center in Bethesda,
Maryland, the Environmental
Autoimmunity Group first will
investigate myositis, a little-
known disorder that causes mus-
cle inflammation and weakness
throughout the human body and
can affect breathing, digestion,
and function of the heart muscle.
Down the road, the team will
broaden its focus to include
other autoimmune disorders
with suspected environmental
triggers, including rheumatoid
arthritis, lupus, type 1 diabetes
mellitus, multiple sclerosis,
scleroderma (a thickening of the
skin), and autoimmune thyroid
disease.
“Members of the group will
work in collaboration with their
colleagues at the NIEHS campus
in North Carolina and those in
other institutes at the Clinical
Center at NIH,” says Perry
Blackshear, NIEHS director of
clinical research, who will work
with the group. Frederick W.
Miller, a specialist in immunology,
internal medicine, and rheuma-
tology, will lead the group in
close association with senior clin-
ical investigator Lisa G. Rider, who special-
izes in immunology, pediatrics, and pedi-
atric rheumatology. Biologist Terrance P.
O’Hanlon and postdoctoral researcher Ejaz
A. Shamim will join them.
According to Miller, scientists have
long suspected that certain genetic and
environmental risk factors can work
together to lead to disease. Myositis—a
chronic, incurable, potentially fatal disease
that afflicts at least 30,000 children and
adults in the United States—may be trig-
gered by infections or exposure to certain
drugs or sunlight in people who are geneti-
cally predisposed. The group’s initial goal
will be to understand the disorder’s possi-
ble genetic and environmental risk factors,
which they plan to accomplish through
several stages of studies. 
“Some studies will have to be hypothe-
sis-generating investigations,” explains
Miller. After that will come cohort–control
studies to compare significant differences
between normal individuals and patients,
followed by further studies to confirm
those results. “To better understand genet-
ic risk factors, we’re also considering a
number of case–control studies using a 
targeted gene approach,” Miller says. He
adds, “In order for us to know how to treat
the disease, we have to know how to mea-
sure the disease.” This will require valida-
tion studies of disease assessment tools.
“This is necessary before we can do a treat-
ment study,” says Miller. 
Myositis, like many autoimmune dis-
orders, is often underdiagnosed for two
chief reasons. First, patients exhibit non-
specific symptoms common to many dis-
eases and disorders (such as muscle or
joint pain and fatigue), or there is no clini-
cal manifestation of the illness until long
into the disease phase. Second, the disor-
ders themselves are rare, and physicians
don’t diagnose disorders they know little
or nothing about. Armed with more
knowledge of the disease, physicians will
eventually stand better equipped to diag-
nose and treat it. But because myositis is
one of the rarest autoimmune disorders,
Miller says, one initial challenge will be
finding enough patients—100 or so for
each study. For that reason, the research
group will collaborate with doctors in
other locations.
The research team will also explore the
possibility that certain autoim-
mune disorders may actually be
collections of a number of so-called
elemental disorders, each with its
own pathogenesis and trigger.
“This may be a major confounder
of current studies,” Miller explains.
There is increasing evidence, he
says, that myositis, rheumatoid
arthritis, lupus, and scleroderma as
they are defined today are actually
aggregate conditions composed of
different elemental disorders.
The new team is unique in that
it will study both adults and chil-
dren. Rider says the team’s focus on
the environment marks a significant
departure from much of past
research on childhood rheumatic
diseases, which has focused more
on genetics. Among other things,
the team will study the roles that
infectious agents and sunlight play
in the development of a form of
myositis called dermatomyositis.
“We’ll also be looking at a phenom-
enon known as microchimerism,
which is the result of migration of
cells between mothers and fetuses,”
Rider says. In microchimerism, a
small number of cells circulating
inside an individual’s body actually
come from another individual’s
body. The most common form of
microchimerism occurs during
pregnancy, when cells from the
fetus’s and mother’s bodies can interchange.
Microchimerism is suspected to play a role
in both myositis and scleroderma. “We sus-
pect that [microchimerism] has a role in
juvenile dermatomyositis and now need to
understand whether it has a role in patho-
genesis,” Rider says.
Rider suspects a number of environ-
mental agents, including silica, mercury,
estrogenic compounds, pesticides, and
others still unidentified may influence
disease. More than likely, multiple envi-
ronmental triggers combine to influence a
single autoimmune disorder. “As these dis-
eases are polygenetic, they are also going to
be polyenvironmental,” she predicts.
–Jennifer Medlin
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Getting a handle on autoimmune disorders. A new NIEHS research
group seeks to understand the gene–environment link in autoimmune
diseases such as rheumatoid arthritis.
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